The trouble with BMS-094 points the way toward the second, and far more difficult, change the industry needs to make.

FORBES: Big Pharma Failures Light the Way to Change

Second, Bristol-Myers Squibb stopped a Phase II study of its BMS-094 for hepatitis C because of a serious safety issue.

FORBES: Big Pharma Failures Light the Way to Change

Bristol is testing it in combination with two other experimental drugs code-named BMS-790052 and BMS-650032 that are in mid-stage trials, and also two earlier-stage compounds.

FORBES

The suit alleges that, despite the negative data, on at least nine occasions during the clinical trial period--January 1998 through November 1999--BMS execs and its paid consultants heaped praises on the drug.

FORBES: Puff Daddies

This compound, a factor Xa inhibitor, was discovered and advanced into the clinic by Bristol-Myers Squibb (BMS).

FORBES: Why Is Pharma Out-Licensing Its Compounds?

Baraclude - After Plavix, Baraclude is the next significant challenge that BMS will have to face immediately.

FORBES: Looking At Bristol-Myers Squibb's Major Patent Expiries That Will Drag On Growth

When BMS was getting ready to start late stage clinical trials, they decided to seek a development and co-marketing partner.

FORBES: Why Is Pharma Out-Licensing Its Compounds?